Latest: FDA Approves New Biosimilar for Oncology Treatment
General Medicine

FDA Approves Neuroimmune Modulation Device for Rheumatoid Arthritis

by HCN Health
0 Comments
0 Mins

After implantation during a minimally invasive outpatient procedure, the SetPoint device is programmed to automatically administer therapy on a predetermined schedule for up to 10 years, simplifying care for people living with RA.

The post FDA Approves Neuroimmune Modulation Device for Rheumatoid Arthritis appeared first on Healthcare Communications Network.

Tags:
HCN Health
Author

HCN Health

Previous Post
Crisis within CDC is spilling into real world, experts say
Next Post
Bruce Willis’ Worsening Battle with Dementia Carries a Clear Clinical Lesson
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago